Racing the Clock: Hemp Industry Scrambles to Build Scientific Case Before 2026 Ban
Cannabis rescheduling, finally brought back to life by President Donald Trump in December, could help revolutionise clinical cannabis research.
The lack of rigorous, scientific research into the complex effects of cannabis on the body has represented the most significant barrier to its wider acceptance as a treatment in the global medical community, and in turn, further integration into mainstream culture.
This is almost entirely the result of prohibition and the barriers it erected for researchers looking into the plant. While rescheduling could help break down these barriers, the incoming ban on ‘intoxicating hemp’ compounds is set to establish plenty more.
On November 12, 2025, President Trump signed legislation ending the longest government shutdown in US history. Buried within the 144-page funding bill was a provision that will, in less than a year, fundamentally reshape, or potentially destroy, America’s $28 billion hemp industry. The new law redefines hemp to ban most intoxicating cannabinoid products, from delta-8 THC to HHC to THCV. It takes effect on November 13, 2026.
Now, with eleven months on the clock, a new partnership is attempting to provide rigorous, data-driven scientific evidence about what these cannabinoids actually do before they endure the same decades-long battle for clarity as cannabis.
Yet, with the clock ticking, traditional clinical trials would only just be getting started before the ban is enacted.
Standard Seed Corporation offers an innovative and potentially transformational alternative. The AI-powered botanical research platform has partnered with the American Healthy Alternatives Association (AHAA), a grassroots hemp advocacy organisation, alongside a growing number of other interested companies, to aggregate consumer data, map molecular interactions, and translate complex cannabinoid science into accessible, digestible information.
The goal isn’t advocacy, according to the partners. It’s filling a dangerous knowledge gap before regulators make irreversible decisions based on incomplete information.
The Data Gap Driving Blanket Bans
When the 2018 Farm Bill legalised hemp, it inadvertently created a loophole that allowed semi-synthetic cannabinoids like delta-8 THC and HHC to proliferate across the United States much faster than research was able to keep up with.
Europe’s recent experience with delta-8 THC illustrates the problem. When European regulators issued their first official position paper on the compound in 2025, their conclusion was stark: we don’t know enough to regulate this any differently than delta-9 THC.
The November funding bill doesn’t just target specific compounds, it creates a sweeping ‘similar effects’ standard that gives federal agencies broad authority to classify any cannabinoid that produces THC-like effects as an illegal substance.
For Kevin Kimmell, B2B Marketing Strategist at Arvida Labs, which manufactures cannabinoid products for brands including Mellow Fellow, the frustration is palpable: “We want to say, hey, this is not just frankenoids or these random cannabinoids.
“We have spent the best part of the last decade developing and perfecting a method of converting cannabinoids safely with no residual solvents or byproducts with our specialist scientific team. Now we’re working on more science to figure out why people like these compounds and what exactly they’re doing.”
Future-Ready: Why Pure Is Building the Cannabis Company Traditional Industry Will Want to Buy Into
February 5, 2026
No Comments
February 5, 2026
No Comments
February 3, 2026
No Comments
Matching Molecules to Real-World Use
The collaboration’s approach centres on pairing two types of evidence that have rarely been combined in cannabis research: computational predictions of how cannabinoids interact with human proteins, and systematic analysis of how thousands of real consumers actually use these products.
Standard Seed’s platform uses artificial intelligence to predict molecular interactions, the same computational drug design techniques used by pharmaceutical companies. The technology can map how a cannabinoid like THCV binds to specific receptor families, which biological pathways it affects, and what outcomes those interactions might produce. Crucially, it can generate these predictions in roughly 30 minutes for new compounds. For example, THCV hits the PPAR Gamma Receptors and Thyroid Hormones which give rise to metabolic effects.
But computational predictions alone aren’t enough. The collaboration pairs Standard Seed’s molecular modelling with real-world consumer data from thousands of product reviews, usage patterns, and reported effects.
Take CBN, widely marketed for sleep. Consumer data shows typical doses around 10 milligrams, with onset times of 30-40 minutes, patterns that align with Standard Seed’s predictions about which neural pathways and receptors the compound affects. Or HHC, where certain isomers appear to interact with the same photosensitivity receptors that regulate circadian rhythm, potentially explaining why consumers report sleep-promoting effects.
“The most enlightening combination is when I have a real-world story, and then we relate that with data,” Coombs notes. “We’re doing real-life clinical trials here, in a way.”
The partnership has developed visual tools to make this complex science accessible. A “Sankey diagram” traces the path from individual cannabinoids through receptor families to biological outcomes to consumer use cases, distilling thousands of molecular predictions into a single reference.
Interactive Demo: Explore the molecular pathways on the Standard Seed platform.
Honest risk assessment
In a significant departure from the catch-all marketing that ultimately drew the ire of politicians, the partners are developing comprehensive warning labels and safety guidelines for minor cannabinoids, and ensuring populations who shouldn’t use them are identified and informed.
The collaboration also plans to publish dosing tables with recommended ranges and upper limits for key cannabinoids.
“Being transparent about risks is super important,” Coombs notes. “We need to avoid just putting across the benefits and not being realistic about the risks.”
By acknowledging genuine risks and appropriate use limitations, the collaboration aims to establish much-needed legitimacy and trust with national regulators.
Racing against the clock
Within 90 days of enactment (by February 10, 2026), the FDA must publish lists identifying which cannabinoids occur naturally in cannabis, which belong to the THC family, and which have THC-like effects.
That February FDA guidance will be crucial. Regulators will need to make scientific determinations about cannabinoid classifications, the precise kind of evidence this collaboration aims to support.
JD McCormick, founder of AHAA, explained: “This collaboration is about giving lawmakers the tools they need to make evidence-based decisions and showing them how those decisions translate into real products that support jobs and families.”
AHAA has mobilised thousands of grassroots supporters and coordinated more than $750,000 in brand donations in 2025 alone to fight hemp restrictions.
The post Racing the Clock: Hemp Industry Scrambles to Build Scientific Case Before 2026 Ban appeared first on Business of Cannabis.
